PRKDC and asthma: We previously showed that PRKDC heterozygosity or moderate treatment with the inhibitor NU7441 markedly protected against asthma-like traits in two animal models of the disease, in part, through the inhibition of Th2 cytokines [8]; however, some Th1 cytokines were affected.